DRREDDY

July 25 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - INVESTS 5.65 BILLION RUPEES FOR 45.19% STAKE IN DRL RUSSIA

Source text: ID:nBSEfgZDN

Further company coverage: REDY.NS

(([email protected];;))

• Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on July 23 for the period ending June 30 2025

• The Hyderabad Telangana-based company is expected to report a 14.6% increase in revenue to ₹88.234 billion from ₹76.96 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹18.00 per share.

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $16.37, about 11.5% above its last closing price of $14.48

This summary was machine generated July 21 at 11:01 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])

July 18 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - USFDA COMPLETES INSPECTION AT DR. REDDY'S SRIKAKULAM FACILITY

• DR REDDY'S LABORATORIES LTD - ISSUED FORM 483 WITH 7 OBSERVATIONS BY USFDA

Source text: ID:nBSE6WH7dN

Further company coverage: REDY.NS

(([email protected];))

Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly

June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.

GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

ELI LILLY

Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.

On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)

(([email protected];))

June 5 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• LIC SHAREHOLDING IN DR. REDDY'S LABORATORIES INCREASES TO 8.216%

Source text: ID:nBSE347R25

Further company coverage: REDY.NS

(([email protected];;))

Adds analyst comment in paragraph 6-7, updates shares

May 12 (Reuters) - Indian pharma stocks .NIPHARM fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug prices by 30%–80% to match other wealthy nations.

Trump said he would sign an executive order on Monday to pursue "most favored nation" pricing.

The U.S. currently pays nearly three times more for many prescription drugs, though Trump offered no implementation details. Several Indian drugmakers earn a significant share of their revenue from North America by selling low-cost generic versions of newer drugs.

Thirteen of 20 stocks on the pharma sub-index fell, led by Sun Pharma’s 4.6% drop, even as the Nifty 50 .NSEI gained 2.5%; Zydus Life ZYDU.NS and Cipla CIPL.NS also declined 0.7% each.

Divi's Laboratories DIVI.NS and Lupin LUPN.NS fell 2% each, while Biocon BION.NS lost nearly 3%.

"A price cut of prescription drugs by 50% or more would hurt the U.S. formulations market, more on the branded size due to immediate potential impact, while over the medium term it will also impact generics as it reduces the potential market size of new drugs," said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.

"Indian branded players like Sun Pharma, Biocon and Zydus Life may see an impact upon strict implementation," Akolkar said.

The U.S. accounts for nearly a third of India's pharma exports, which rose 16% to about $9 billion last fiscal year, according to government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Nivedita Bhattacharjee and Mrigank Dhaniwala)

(([email protected]; 8800437922;))

April 14 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DENIES 25% WORKFORCE COST REDUCTION CLAIM

Source text: ID:nBSE66Xcjy

Further company coverage: REDY.NS

(([email protected];;))

Adds analyst comments in paragraphs 11-12, updates share moves throughout

By Manas Mishra and Ananta Agarwal

April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.

Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.

The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.

Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.

In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.

Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.

"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.

"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."

Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.

ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION

Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.

Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.

If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.

EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.

Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.

IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.

(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)

(([email protected]))

By Rishika Sadam

HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly LLY.N in the populous nation, two sources familiar with the plans told Reuters.

Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India "this year, probably in the next few months," sources told Reuters on condition of anonymity as they were not authorized to talk to the media.

"Novo's also assessing the stock situation to handle the demand in India. They want to avoid any shortage issues," one of the sources said.

The company's accelerated plan follows U.S. rival Eli Lilly's launch of its diabetes and obesity drug Mounjaro in India last month.

Reuters reported earlier that Novo's India team had been pushing the global headquarters for an early Wegovy launch.

Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers to among the world's most valuable companies.

The competing drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving way for generic drugmakers to produce cheaper versions of the drugs.

Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS and Dr Reddy's REDY.NS have been racing to build up supplies with an eye on a share of a global market analysts have estimated could be worth $150 billion annually in the next decade.

Novo declined to comment on Monday, but previously said Wegovy has been approved in India. It did not have a confirmed date for the medicine's India launch at the time.

"Novo also thinks that its brand names Ozempic, Wegovy have better penetration in the market, which would give them an edge," the other source said.

Still, Novo would need to offer the drug at a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial, and $40 for a 2.5 mg vial, the lowest doses.

(Reporting by Rishika Sadam in Hyderabad and Maggie Fick in London; Editing by Bill Berkrot)

(([email protected];))

By Kashish Tandon

April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.

"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.

"That will be announced in the near future, and is under review right now," Trump said.

The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.

All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.

Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.

Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.

Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.

However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.

"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.

Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.

Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

(([email protected]; 8800437922;))

Updates shares to U.S. market open

By Maggie Fick and Kashish Tandon

LONDON/BENGALURU April 3 (Reuters) - Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it was premature to celebrate as tariffs were still likely to come.

Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.

Shares of U.S. drugmakers AbbVie ABBV.N and Johnson & Johnson JNJ.N rose about 2%, defying the broader market drop.

Across continents, shares of Indian and European drugmakers .SXDP rose, in a sign of relief that pharmaceutical products for now remained out of the crosshairs of the trade wars.

A U.S. official said on Wednesday the president plans separate tariffs targeting the pharma sector.

Trump in his White House Rose Garden announcement once again namechecked the industry, predicting that pharma companies will come "roaring back" to the U.S, and warning if they don't, "they got a big tax to pay".

"The administration has reinforced the need to maintain robust and resilient domestic manufacturing capacity in pharmaceuticals," Stephen Farrelly, global pharma & healthcare lead at ING. "So it is being highlighted as a sector they needs to reshore."

WORRIES PERSIST

Many in the industry predicted the recent uncertainty over tariffs would continue to cast a shadow over drugmakers.

"The only thing that feels certain is more uncertainty," Barclays analyst Emily Field told Reuters.

One source at a European drugmaker said the sense on pharma sector tariffs was: "It's not today, but it's coming."

Trump's executive order listed pharmaceuticals alongside lumber, semiconductors and other sectors that could be subject to investigation under Section 232 of the 1962 U.S. Trade Act.

U.S. manufacturing costs for pharma companies will rise as country-specific tariffs will affect key supplies such as organic chemicals and glassware used to make pharma products, Bernstein analysts said in a note. They calculated an additional $45 billion of import cost risk to the pharma industry.

Jefferies analysts said Biogen BIIB.O and Amgen AMGN.O were among the drugmakers with most ex-U.S. exposure, while UBS pointed to AbbVie ABBV.N and Merck MRK.N having significant overseas manufacturing.

Medical devices and diagnostics equipment did not appear to be exempted, and shares in companies including GE Healthcare GEHC.O and DexCom DXCM.O fell about 6%.

Medical device industry group AdvaMed said the tariffs would likely lead to cuts in research and development spending and threatened the U.S. position as a leader of innovation in the medtech sector.

(Reporting by Maggie Fick in London, Rishika Sadam in Hyderabad, Bhanvi Satija and Kashish Tandon in Bengaluru, Additional reporting by Manas Mishra in Bengaluru, Paul Arnold in Zurich, Dominique Patton in Paris and Deena Beasley in Los Angeles; Editing by Savio D'Souza, Mark Potter and Arun Koyyur)

(([email protected]; 8800437922;))

Updates March 20 story with Novo Nordisk comment on Wegovy launch timing in paragraph 11

By Rishika Sadam

HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

U.S.-based Lilly LLY.N and Danish Novo Nordisk NOVOb.CO have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.

A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor's prescription.

Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month's supply if customers pay directly in cash without any third-party entities.

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the U.S.

Lilly, however, said that the pricing in different geographies cannot be compared given significant variation in healthcare systems, economies and reimbursement policies in each country.

"(Mounjaro) launch is ahead of Novo Nordisk and the first mover advantage should help ... but pricing seems high (for the Indian market). At the highest dose, a patient will have to spend close to 700,000 rupees (around $8,100) per annum," Vishal Manchanda, analyst at Systematix Institutional Equities said.

Novo's weight-loss drug, Wegovy, can cost non-insured U.S. patients more than $1,000 a month.

Novo's India team has been pushing the global leadership to launch Wegovy as early as 2025 in the country as opposed to the company's target of a 2026 launch.

The drugmaker told Reuters that Wegovy has already been approved in India, but said it did not have a confirmed date for the medicine's launch there.

The company's shares were down 0.6% at 1145 GMT, underperforming the broader European market .STOXX. Shares of U.S.-based Lilly rose as much as 2.07% to $854.39 on Thursday.

Novo's stock has fallen over 12% so far this year, while Lilly's has jumped 8%.

Novo is not the only competition Lilly will have to confront in India. Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS, Dr. Reddy's REDY.NS and Lupin LUPN.NS have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.

Obesity and diabetes rates in India, a country of more than 1.4 billion people, have been steadily climbing. The number of adults with diabetes is set to increase to over 124 million by 2045 from 74.2 million in 2021, according to International Diabetes Federation.

Meanwhile, a government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.

Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

($1 = 86.3425 Indian rupees)

(Reporting by Rishika Sadam in Hyderabad, Maggie Fick in London and Bhanvi Satija in Bengaluru; Additional reporting by Manvi Pant in Bengaluru; Editing by Janane Venkatraman, Alan Barona and Tomasz Janowski)

(([email protected]; [email protected]))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

March 18 (Reuters) - Alvotech SA ALVO.O:

• ALVOTECH AND DR. REDDY'S ANNOUNCE FDA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION FOR AVT03, A PROPOSED BIOSIMILAR TO PROLIA® AND XGEVA®

Source text: ID:nGNERlH6z

Further company coverage: ALVO.O

(Gdansk Newsroom)

(([email protected]; +48 58 7696600;))

March 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - RECALLS LEVETIRACETAM INJECTION IN U.S.

• DR REDDY'S LABORATORIES LTD - RECALL DUE TO MISLABELING OF INFUSION BAG

• DR REDDY'S LABORATORIES LTD - NO ADVERSE EVENTS REPORTED RELATED TO RECALL

• DR REDDY'S LABORATORIES LTD - MISLABELED PRODUCT MAY CAUSE SERIOUS ADVERSE EVENTS

• DR REDDY'S LABORATORIES LTD - RECALL EXECUTED WITH KNOWLEDGE OF U.S. FDA

• DR REDDY'S - DUE TO MISLABELING OF INFUSION BAG

Source text: ID:nBSEYZGPz

Further company coverage: REDY.NS

(([email protected];;))

March 4 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• ACQUIRES 14 ANDAS FROM DR. REDDY'S LABORATORIES

• ACQUISITION INCLUDES 13 APPROVED ANDAS AND 1 PENDING APPROVAL

• ADDRESSABLE OPPORTUNITY OF ACQUIRED ANDAS IN USA APPROX. $421 MILLION

Source text: ID:nBSEcxCc7

Further company coverage: SENO.NS

(([email protected];;))

By Rishika Sadam and Kashish Tandon

MUMBAI/BENGALURU, Feb 28 (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's CIPL.NS top executive said on Friday, as the industry braces for U.S. President Donald Trump's plans to tax pharmaceutical imports.

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of popular drugs.

"I'm not sure tariffs should dictate what we should be doing as players, because there is a risk that four years later, those tariffs may go away," Cipla Global CEO Umang Vohra said at the Global Pharmaceutical Quality Summit in Mumbai.

"So by the time you build a plant, tariffs have gone away. Now you have a plant sitting there, right? So I just think we should take a more holistic view."

Trump has said he could impose duties of 25% or more on pharmaceutical imports and an announcement could be made by next month. He also asked companies to shift manufacturing to the U.S. to avoid tariffs.

Most drugmakers said they were awaiting clarity on what kind of tariffs would be imposed, if any.

"I don't know how much difference it (tariffs) will make to us... and will not justify relocating our manufacturing," said Sun Pharma SUN.NS MD Dilip Shanghvi.

"Ultimately, it (tariff impact) will be passed on to consumers," Shanghvi said.

India imposes an about 10% tax on pharma imports from the U.S. while paying almost nothing on exports of its pharmaceutical products into the U.S., according to industry experts.

India makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries, and the U.S. is its biggest market, government data shows.

According to research firm IQVIA, nearly half of all prescriptions for generic medicines in the United States in 2022 were supplied by Indian drugmakers. Overall, generic drugs saved the U.S. health system about $408 billion.

Earlier this week, Dr Reddy's MD GV Prasad told Reuters Indian drugmakers are likely to remain competitive in the generics market even if Trump levies a duty on pharmaceutical imports.

He had also said shifting manufacturing to the U.S. was not practical as they do not have enough capacity and costs would rise.

(Reporting by Rishika Sadam in Mumbai; Writing by Kashish Tandon; Editing by Devika Syamnath)

(([email protected];))

By Kashish Tandon, Bhanvi Satija and Rishika Sadam

HYDERABAD Feb 26 (Reuters) - The rising adoption of artificial intelligence in the pharmaceutical industry dominated discussions at a conference in India this week, while executives largely preferred to wait for more clarity on U.S. President Donald Trump's tariff threats.

Drugmakers such as Amgen AMGN.O and contract manufacturers including Parexel highlighted AI's role in reducing the time taken to conduct certain parts of the trials.

U.S.-based Parexel said it was piloting an AI model to generate drug safety reports 30-45 minutes faster than the manual process. The AI-generated reports are then verified by an expert.

AI can help halve the cost and time taken to develop a drug, from discovery through commercial production, compared to the traditional process, said Chaitanya Royyuru, partner at consulting firm EY. Royyuru estimated that the process currently takes more than 10 years and costs about $1 billion.

Discovering new molecules and drug repurposing, or using a drug for a condition outside of its approved indication, are other areas where AI is being utilized, executives said.

Beyond drug discovery processes, AI is also being used in medical image reading, where it is able to assist doctors in finding anomalies.

"Sometimes, when we look at an X-ray and we think it's normal, but AI says look, there's a small cancer you're missing," said Nageshwar Reddy, chairman, Asian Institute of Gastroenterology.

"And when we actually look at it very carefully and follow the patient, there's a cancer coming there," Reddy said.

Ken Washington, chief technological officer, Medtronic, said, "The bottom line is that AI has to be everybody's job."

WAIT AND WATCH ON TARIFFS

Trump's plans to levy tariffs on pharmaceutical imports had cast a shadow over the two-day conference as India is among the top exporters to the U.S., especially of cheaper versions of popular drugs.

However, drugmakers including Dr Reddy's REDY.NS said they were still waiting for clarity on the tariffs.

"Right now, it's wait and watch. There is no clarity on what the tariffs are, if any, or if there is a transition period," said Nandini Piramal, chairperson at Piramal Pharma, which provides contract manufacturing and development services.

(Reporting by Kashish Tandon, Bhanvi Satija and Rishika Sadam in Hyderabad; Editing by Sriraj Kalluvila)

(([email protected]; Outside U.S. +91 9873062788;))

Feb 25 (Reuters) - Indian drugmakers are likely to remain competitive in the generic drugs market in the face of U.S. President Donald Trump's plans to levy tariffs on pharmaceutical imports, Dr Reddy's Managing Director GV Prasad said on Tuesday.

The Indian pharmaceutical industry is still waiting for more clarity on any tariffs before taking any action given a lack of details, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana. The tariffs would likely raise costs for U.S. consumers or middlemen, he added.

"In reality, to shift all these products from worldwide into the United States is not practical. They don't have that much capacity, and their costs will rise. Even with tariffs, I think Indian and Chinese companies would be competitive."

(Reporting by Rishika Sadam in Hyderabad; Writing by Manas Mishra; Editing by Janane Venkatraman )

(([email protected]; www.twitter.com/Manaswrites15;))